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The human body consists of hundreds of kinds of cells specified from a single genome 
overlaid with cell type-specific epigenetic information. Comprehensively profiling 
the body’s distinct epigenetic landscapes will allow researchers to verify cell types 
used in regenerative medicine and to determine the epigenetic effects of disease, 
environmental exposures and genetic variation. Key marks/factors that should be 
investigated include regions of nucleosome-free DNA accessible to regulatory factors, 
histone marks defining active enhancers and promoters, DNA methylation levels, 
regulatory RNAs, and factors controlling the three-dimensional conformation of 
the genome. Here we use the lung to illustrate the importance of investigating an 
organ’s purified cell epigenomes, and outline the challenges and promise of realizing 
a comprehensive catalog of primary cell epigenomes.
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Published online: 15 June 2016
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A single fertilized human egg, providing 
a single diploid genome, gives rise to a vast 
array of cells, recently estimated to be about 
37 trillion [1]. These cells are thought to rep-
resent over 210 histologically distinct cell 
types, most organized in complex higher 
order structures that form highly specialized 
organs [2]. A key question in human biology 
is how these distinct cell types are derived 
and maintained during development and 
adulthood. Because the genomic informa-
tion in all cells is identical (excepting specific 
genetic rearrangements such as immuno-
globulin gene recombination in B cells), the 
distinct phenotypic properties of different 
cell types in an organ must be acquired by 
restricting accessibility to the genetic code 
in a cell type-specific and dynamic man-
ner. This is accomplished by the epigenome, 
defined as the information overlaid on the 
genome that blocks access to certain regions 
and opens others to gene expression. Epig-
enomic information encompasses chemical 
modifications of DNA such as DNA meth-
ylation and hydroxymethylation, proteins 
bound to the DNA such as transcription fac-
tors that populate promoters and enhancers, 
modifications of the histones that make up 
the nucleosomes, nucleosome remodeling 
complexes, proteins that influence the three-
dimensional organization of the genome such 
as lamins and CTCF, and numerous noncod-
ing regulatory RNAs (Figure 1). Together, 
these epigenetic factors constitute the epig-
enome and specify and maintain the differ-
ent cell types in the body. The analysis of 
the epigenome can provide insight into dis-
ease risk and onset when affected cell types 
are compared with their healthy (reference) 
counterparts. While the cost of sequencing 
may necessarily limit which features can be 
profiled for many different cell types, the epi-
genetic marks in Table 1 are widely accepted 
as defining regulatory regions of DNA. In 
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Figure 1. Mechanisms of epigenetic control. The epigenome allows cell types with identical genomes (schematically depicted at the 
top) to exhibit differential gene expression patterns through a variety of mechanisms. They include, from left to right: regulatory 
RNAs of different types such as long noncoding RNAs, miRNAs and others; recruitment of transcription factors that can activate gene 
expression; enhancer-binding proteins that can activate gene expression by looping to promoters in cis or in trans (when different 
chromosomes interact); proteins like CTCF that mediate looping interactions in concert with other proteins such as cohesin and 
thereby support the three-dimensional organization of the genome; the binding of repressor proteins that can silence genes; DNA 
methylation that is usually absent in active regulatory regions such as promoters and enhancers (hydroxymethylation, thought to 
occur during DNA methylation removal, and other modifications can also occur); a variety of histone modifying enzymes that lead to 
protein interactions associated with different chromatin states; nucleosome remodeling complexes that can lead to the removal or 
deposition of nucleosomes in active and repressed genomic regions, respectively.
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the following sections we use the lung as an example 
to highlight the importance of understanding the 
epigenetic basis for cell phenotype specification, and 
describe specific instances in which cell type-specific 
epigenomic information might be leveraged: in tissue 
regeneration research, in determining disease states 
compared with healthy progenitor cells, in assessing 
the consequences of environmental exposures and in 
identifying functional noncoding variants associated 
with disease risk in genome-wide association studies 
(GWAS).
Examination of purified cell types is crucial 
for tissue regeneration research
The availability of human embryonic stem cells (ESCs) 
and induced pluripotent stem cells has opened avenues 
for in vitro differentiation of different tissues and cell 
types, so that repair and regeneration of all tissues is 
becoming a reality. However, derived cells and tissues 
must properly recapitulate the natural state and pheno-
type, or they may put patients at risk for tissue degener-
ation, malfunction, or possibly even cancer [12]. Analy-
sis of the epigenomes of numerous established human 
ESC lines has shown abundant epigenetic abnormali-
ties, indicating that culture conditions might predis-
pose cells to neoplastic transformation [13]. Whether 
the proper phenotype of progenitors or differentiated 
cells derived from stem cells has been achieved can be 
assessed by examining whether the epigenome (and 
thereby the transcriptome) of the derived cells mirrors 
those of the desired target cell. However, this requires 
that the epigenomes of stem cells and target cells be 
well characterized. The Roadmap Epigenome project 
and the ENCODE project have made progress in this 
effort [6,13]. Among the 111 analyzed cell types in the 
Roadmap Epigenome project are induced pluripotent 
cells, human embryonic stem cells and several derived 
progenitor cells. However, the characterization of indi-
vidual cell types that make up complex organs is in its 
very early stages. Due to the difficulties in purifying 
www.futuremedicine.com 819future science group
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large numbers of individual cell types, initial efforts 
to elucidate organ-specific epigenomes have focused 
largely on the characterization of tissues samples con-
sisting of mixed cell populations. While this provides a 
good starting point, the resulting data reflects an aver-
age epigenome that may be based on vastly differing 
epigenomes of distinct cell populations [14–16]. A lim-
ited examination of purified cell populations has taken 
place, including numerous immortalized or cancerous 
human cell lines and several fully differentiated puri-
fied cell types, such as skin keratinocytes, skin fibro-
blasts and melanocytes [17–19]. Although collectively 
these efforts have provided key insights into tissue-
specific epigenomic differences, it remains largely 
unknown how the individual cell types within each 
organ contribute to the average epigenomes obtained 
for these tissues.
Identifying disease-associated epigenetic 
aberrations will require knowledge 
of progenitor cells & establishment of 
reference epigenomes
Numerous human diseases have been associated with 
epigenomic abnormalities, including diabetes [20,21], 
sepsis [15], mental illnesses [16,22–25] and all types of can-
cer [26]. While promising, challenges to future similar 
studies are at least threefold:
•	 Difficulties related to obtaining pure populations 
of diseased cells from patient tissues;
•	 Debate around true cells of origin for many diseases; 
and
•	 The dearth of comprehensive reference or ‘baseline’ 
epigenomes even in scenarios in which the 
progenitor cells of disease are undisputed.
Studies of cancer illustrate all three examples. First, 
the simple objective of obtaining pure populations of 
‘tumor’ and ‘normal’ cells is complicated by the fact 
that the tumor mass is comprised of a heterogeneous 
cell mixture comprising connective tissue, blood ves-
sels and infiltrating lymphocytes. In addition, tumor 
samples are often compared with adjacent noncancer-
ous tissue in the same patient, which can also be com-
prised of numerous cell types. Mathematical models 
for dealing with tissue heterogeneity using DNA meth-
ylation signatures have been developed and can address 
this problem to a certain extent [14,18,19]. Heterogene-
ity can also be minimized by expert pathologists and 
accurate microdissection of clinical samples, however, 
this may come at the expense of sufficient starting 
material for downstream sequencing. Despite these 
efforts, it remains a challenge to obtain purified cell 
types, particularly where large epidemiological studies 
are concerned.
Secondly, the cell type of origin for many diseases 
may not be known. Moreover, even if the cell type of 
origin is known, such cells may be rare in samples of 
noncancerous tissue [27,28]. The latter would be true if 
the cell type of origin is a stem cell present in the tis-
sue of interest, or if it represents a very small fraction 
of cells in normal tissue. A prime example is small-cell 
lung cancer (SCLC), a very aggressive cancer found 
predominantly in smokers. SCLC arises from rare 
pulmonary neuroendocrine cells which lie in small 
clusters along the airways, as discussed below [29]. 
Even though epigenomic profiles of SCLC have been 
described [30,31], it is unclear which aspects are abnor-
mal because the epigenomes of the healthy reference 
cell populations have not been obtained.
Measuring the effects of environmental 
exposures requires knowledge of the 
baseline epigenomes of unexposed cell 
types
Studies of mono- and dizygotic twins have been partic-
ularly informative in illustrating the profound effects 
of epigenomic variation on human health and the role 
of the environment in inducing this variation [25,32,33]. 
In Alzheimer’s disease (AD), early life epigenetic 
changes may predispose to neurological disease at a 
later time, based on DNA methylation and oxidative 
status of certain gene promoters [22,23,34]. Fetal alcohol 
exposure may also affect DNA methylation patterns 
and ensuing disease [35]. Lung diseases are particularly 
associated with exposure to airborne environmental 
agents, including cigarette smoke and traffic-related 
air pollution such as diesel exhaust. These exposures 
are implicated in diseases like asthma, chronic obstruc-
tive pulmonary disease (COPD), emphysema and lung 
cancer. Exposures can occur in utero, in childhood or 
in adulthood, and the age at which exposures occur 
may affect the extent of epigenetic changes. The fact 
that some tissues, including lung and reproductive tis-
sue, develop throughout adolescence and are affected 
by environmental influences, underscores the impor-
tance not only of determining the epigenomes of 
adult tissues, but also those of cells from embryos and 
children.
One very interesting example of environmental 
effects on the epigenome is the population-based anal-
ysis of DNA methylation patterns in smokers versus 
nonsmokers [36,37]. DNA methylation has been favored 
as the investigated epigenetic mark because it can be 
determined from purified DNA, which is often the only 
available biological material in epidemiological studies. 
www.futuremedicine.com 821future science group
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However, instead of DNA obtained from lung cells, it 
is usually derived from blood cells that are frequently 
used as a surrogate; in many studies is too costly to 
obtain, store, and analyze multiple tissue types. Using 
white blood cell DNA, modest but reproducible DNA 
methylation changes have been observed in numerous 
studies [36]. Some of these changes are rapidly revers-
ible upon cessation of exposure, and others can persist 
for many years, as determined in studies from children 
exposed in utero and adults examined at different 
time points following smoking cessation [38,39]. Since 
the blood cells from which DNA was isolated were 
not usually sorted by cell type, an important question 
is whether the observed DNA methylation changes 
could largely be related to changes in the relative cell 
type composition of the white blood cells, as recently 
observed [40]. Corrections for cell type composition are 
thus required [18,19]. Another key question is whether 
epigenetic changes seen in the blood reflect changes 
and disease risk in the lungs. We have recently inves-
tigated smoking-associated DNA methylation changes 
using samples of histologically normal lung from lung 
cancer patients (unpublished observations). Among 
others, we detected hypomethylation of cg05575921, 
which lies in an AHRR intron. This same hypomethyl-
ation event has also been observed in numerous studies 
of the white blood cell DNA of smokers [36]. Because 
we were not able to analyze purified lung cell types we 
do not know which cells contributed to the observed 
DNA methylation changes. However, we were able 
to exclude the possibility that hypomethylation 
merely reflects changes in tissue composition (such as 
immune cell infiltration) rather than epigenetic altera-
tions because we carried out functional studies. This 
illustrates the importance of measuring environmental 
responses in individual cell types and having clearly 
established baseline epigenomes in such cells.
Interpretations of the effects of genetic 
polymorphisms on disease risk requires 
knowledge of epigenetic marks in the 
risk-associated cell types
Genetic variants can affect the epigenome in many 
ways [41–43]. For example, variants in the coding 
regions of genes involved in establishing or maintain-
ing epigenetic features, such as DNA methyltransfer-
ases [44–48] or histone-modifying enzymes [49] have 
been reported to affect the epigenome on a broad scale, 
and are frequently detected as somatic mutations in 
tumors [50–52]. Germline variants have been reported 
to affect the epigenome at discrete loci in more subtle 
ways [43,53–55].
Genome-wide association studies (GWAS) per-
formed with microarrays containing millions of probes 
for SNPs have identified over 8000 variants associated 
with human illness [56,57]. Mechanistically connecting 
GWAS SNPs to disease processes is complicated by 
two main factors [56,58]:
•	 Most are co-inherited with hundreds of variants in 
linkage disequilibrium (LD) that could be more 
causal than their representative or ‘index’ SNP on 
the array; and
•	 Most GWAS and associated LD SNPs lie outside of 
coding regions of genes, making hypotheses about 
their function more elusive than for coding SNPs.
Several recent in-depth follow-up studies support 
the notion that functional noncoding SNPs reside in 
regulatory regions of the genome, such as gene enhanc-
ers, which orchestrate transcriptional programs under-
pinning health and disease. In all of these studies, the 
epigenomic features of disease-relevant cell types were 
profiled and integrated over the locations of GWAS 
and LD SNPs. This resulted in a shortlist of potential 
SNP candidates to prioritize in functional follow-up 
experiments that range from allele-specific ChIP and 
reporter gene assays [53,54] to genome-wide expression 
studies following CRISPR-driven deletion of enhanc-
ers overlapping risk SNPs [55]. To date, noncoding 
functional SNPs have been reported to disrupt tran-
scription factor binding sites and enhancer-promoter 
interactions [53,55], affect DNA methylation [43,59], 
modulate miRNA and lncRNAs expression and 
binding [60,61] and affect CTCF occupancy [62].
The importance of evaluating GWAS SNPs in dis-
ease-relevant epigenomic contexts is evident in disor-
ders of the respiratory tract. The lungs (as discussed 
in more detail in the section below) consist of many 
epithelial cell types that can be broadly categorized as 
‘airway’ or ‘alveolar.’ These broad categories harbor 
subgroups of highly specialized cell types with dra-
matically distinct phenotypes, epigenomes and dis-
ease predispositions [1,63–68]. For example, epithelial 
cell types lining the conducting airways and bron-
chioles are implicated in squamous cell lung cancer 
(SQLC) and disorders related to bronchitis [27,28,69]. 
Conversely, AT2 cells of the alveolar compartment 
are thought to give rise both to lung adenocarcinoma 
(LUAD), the major subtype of lung cancer, and idio-
pathic pulmonary fibrosis (IPF), a deadly illness in 
which the alveoli are destroyed and replaced by scar 
tissue [70,71]. Interestingly, the C-allele of rs2736100, 
located in an intron of the telomerase-encoding 
TERT gene, is linked to increased risk of LUAD but 
not SQLC or other lung cancer subtypes in GWA 
studies [72,73]. In contrast, the rs2736100-A allele is 
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the only risk SNP that replicates in GWA studies of 
IPF [74]. Heightened telomerase activity is a well-doc-
umented phenomenon in tumor predisposition [75], 
while decreased activity is linked to epithelial stem 
cell exhaustion and tissue remodeling seen in emphy-
sema and IPF [76,77]. Not surprisingly, the rs2736100-
C allele is associated with elevated TERT expression 
in lung tissue [73], while the rs2736100-A allele is 
associated with shortened telomeres that are a hall-
mark of IPF [78–80]. Epigenomic aberrations have been 
associated with LUAD and IPF at disparate loci in 
several reports [81–83]. Animal models of both disor-
ders exist [84,85], and epigenomically profiling labeled 
AT2 cells at different stages of disease progression 
might provide actionable insight into the mechanism 
whereby rs2736100 deregulates telomerase. Likewise, 
epigenomic profiles may elucidate the role of other 
causal SNPs elsewhere in the genome.
The complexities of determining 
comprehensive organ-specific epigenomes: 
the lung as an example
To address the challenges described in the above sec-
tions, the epigenomes of all cell types in the human 
body would need to be mapped. Ideally, this should be 
performed by experts in cell purification in an organ-
by-organ fashion. In this section, we provide a brief 
overview of the types of cells found in the lung to illus-
trate the complexity of dissecting the epigenomes of 
cells comprising whole organs. In the lungs, there are 
over 40 different types of cells ranging from a variety 
of epithelial cells to smooth muscle cells, cells compos-
ing the vasculature and lymphatic system and immune 
cells defending the airways against foreign particulate 
matter and pathogens (Figure 2) [1,63–68]. As outlined in 
the sections of this review, the individual epigenomes 
of the different cell types could be used for numerous 
purposes, including comparison to regenerated tis-
sues and diseased cells, to identify the consequences 
of environmental exposures and to gain insights into 
the effects of genetic diversity (Figure 2, right side). An 
example illustrating the importance of characterizing 
cell type-specific epigenomes is given in the bottom 
panel of Figure 2, which compares ChIP-seq data for 
histone 3 lysine 27 acetylation (H3K27Ac, a mark indi-
cating an active enhancer) in small airway epithelium, 
normal human lung fibroblasts and unpurified adult 
lung tissue. It indicates the presence of an enhancer 
downstream of the FHAD gene in small airway epithe-
lial cells but not in lung fibroblasts; the element is not 
clearly detectable in adult lung, which is a mix of many 
different cell types. This point is further underscored 
by studies of two epithelial populations in human 
peripheral lung, AT1 and AT2 cells; dramatic differ-
ences can be observed between their epigenomes even 
though they are derived from two cell types linked by a 
direct progenitor-progeny relationship and co-existing 
in close proximity in the same organ compartment [86].
The airways begin with the trachea, which connects 
the throat to the primary bronchi. The latter start at 
the bifurcation to both lungs and branch out into the 
secondary bronchi connecting to the lung lobes (three 
on the right and two on the left in humans due to the 
presence of the heart). This is followed by the tertiary 
bronchi, which transport the air into lung segments. 
The bronchioles follow, transitioning into the termi-
nal bronchioles, considered the smallest parts of the 
airways. The transition to the alveoli occurs through 
the respiratory bronchioles. Cell types found in the 
airways play numerous roles, and are often divided 
into categories based on their function [63–68]. Basal 
cells lie on the basement membrane and are thought to 
be involved in airway regeneration upon injury. They 
are also implicated as progenitors of squamous cell car-
cinoma [28]. A variety of secretory cells defend against 
pathogens and offer protection against contaminants. 
These include: serous cells, which produce lysozyme, 
albumin and antileukoprotease, and are implicated 
in lung repair upon injury; goblet cells, which secrete 
mucus and have numerous membrane-bound secre-
tory granules; and club cells, which express detoxify-
ing enzymes, the characteristic protein uteroglobin 
(CC10) and secrete surfactant. Other epithelial cell 
types found in the airways include ciliated cells, whose 
function is to move mucus up and out of the airways, 
thereby ridding the lungs of particulate matter and 
pathogens, and chemosensory cells, including pul-
monary neuroendocrine cells (PNECs) and the pear-
shaped brush cells. The latter two cell types are rare, 
each accounting for less than 1% of lung epithelial 
cells. PNECs are thought to function in oxygen sens-
ing and as mentioned have been very strongly impli-
cated as the cell of origin of SCLC [29]. The function 
of brush cells remains enigmatic. It is interesting that 
they express proteins of the taste transduction path-
ways, and this may be related to the sensing of patho-
gens [87]. In addition to the epithelial cells listed above, 
the airways are lined with smooth muscle, which allow 
the bronchioles in particular to expand and contract 
in response to exercise or inhaled particulates respec-
tively. Connective tissue and the vascular and lym-
phatic systems surround the airways. Lastly, immune 
cells populate the airways, consisting of specialized 
macrophages and dendritic cells. The relative cell 
composition in the upper and lower airways differs, 
and it has been suggested that even single cell types 
like basal cells might differ phenotypically dependent 
on their proximal or distal location [64].
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The alveolar compartment has fewer epithelial cell 
types. The cellular composition of the human respi-
ratory bronchiole has been poorly characterized but 
is thought to include club cells and rare ciliated cells. 
The large delicate AT1 cells constitute the respiratory 
surface (approximately 95% of the alveolar surface 
area) and are in intimate contact with the capillary 
network, while cuboidal AT2 cells produce surface 
tension-reducing surfactants that prevent the alveo-
lar sacs from collapsing upon exhalation. In addition, 
AT2 cells are thought to play a role in peripheral lung 
regeneration upon injury and can transdifferentiate 
into AT1 cells [88]. This process can be recapitulated 
in vitro over the course of 6–8 days and was used by 
us to obtain human AT1 cells for epigenomic profiling 
because the fragile primary human AT1 cells are very 
difficult to purify in large numbers [86,89]. AT2 cells are 
the presumed precursors of lung adenocarcinoma [70]. 
As with the airways, numerous other cells are present: 
interstitial cells (fibroblasts), a large number of vascu-
lar and lymphatic cells, limited smooth muscle, and 
alveolar macrophages and dendritic cells. The latter 
are distinct from other macrophages in the body and 
should be independently studied [90].
From these observations it is clear that samples of 
lung tissue will contain many different cell types. 
How much of each type is present in a piece of tis-
sue depends on the sampled location and the natural 
abundance of each cell type. In an analysis of cell type 
numbers in an adult human lung, endothelial cells 
were most numerous (∼140 billion), followed by AT2 
cells (∼70 billion), AT1 cells (∼40 billion) and alveo-
lar macrophages (∼30 billion) [1]. All airway cells are 
at least an order of magnitude less common, with the 
chemosensory cells in lowest abundance.
In order to determine the epigenomes for all the cell 
types in the lung, each must be separately purified and 
characterized, a process that can be challenging for del-
icate cells or cells of relatively low abundance. How this 
can be approached will be discussed in the next section. 
Given the technical difficulty and expense of such puri-
fications, they do not lend themselves to be carried out 
for numerous subjects, for example, for epidemiologi-
cal studies. Rather, the goal would be to use purified 
epigenomes from a limited number of individual lungs 
to identify regulatory elements in regions that may be 
implicated based on epidemiological studies.
New approaches to obtaining 
cell-type-specific epigenomes
When attempting to characterize purified human epig-
enomes, it is of course desirable to obtain primary cells, 
although for some fragile cell types such as AT1 cells, 
this can be challenging. In initial epigenomic studies 
of the peripheral lung, low-cell-number methods for 
epigenomic mapping were not yet available, requir-
ing the purification tens of millions of cells to capture 
high quality data for each histone mark by chroma-
tin immunoprecipitation-high throughput sequenc-
ing (ChIP-seq) [86]. Such cell quantities can only be 
obtained from a deceased person. Because remnant 
transplant lung was used, the donors had often been on 
life support for several days. Despite the unnatural con-
ditions, lungs that have been maintained in this way are 
successfully transplanted into patients, indicating that 
lung function is sufficiently maintained. For our exper-
iments, remnant transplant lung that was disease-free 
was transported by air to the laboratory where it was 
lavaged to remove macrophages. These can be saved for 
independent profiling. The lung was then digested with 
elastase, using a procedure adapted from the Matthay 
laboratory [86,91]. The tissue was subsequently chopped, 
filtered and subjected to gradient centrifugation. Any 
remaining immune cells were then removed by panning 
on IgG-coated plates and AT2 cells were purified on 
epithelial cell adhesion molecule-carrying microbeads. 
This yielded very large numbers of AT2 cells that were 
approximately 90% pure. Because AT1 cells are too 
fragile to purify in large quantities, their in vitro equiv-
alent was obtained by plating AT2 cells and allowing 
them to spontaneously differentiate [86,89]. Dramatic 
transcriptional changes occurred within two days of 
plating and by 6 days the cells had attained an AT1 
cell-like phenotype and had formed tight junctions as 
measured by transepithelial resistance. Culturing cells 
to obtain derivative cell types introduces potential vari-
ables, but it may be the only way large numbers of some 
cells can be obtained. This type of approach has been 
successfully used to grow cells from organs such as the 
kidney, brain and colon with maintenance of the proper 
cell characteristics [92–95]. In the case of peripheral lung, 
it allowed us to profile AT2 cells and AT1-like cells for 
DNA methylation, numerous histone marks and open 
chromatin, the latter by formaldehyde-assisted iden-
tification of regulatory elements (FAIRE)-seq, which 
allows one to use remnant material from the ChIP 
experiments. However, dealing with the large number 
of cells that was needed limited the ability to purify 
additional cell types simultaneously.
Fortunately, important progress has been made, not 
only in high throughput sequencing technologies but also 
in low-cell-number approaches. This means that FACS, 
which is too cumbersome and expensive to use for obtain-
ing very large numbers of cells, is now a viable option 
for cell purification. Combined with the development of 
new low-cell-number methods for epigenomic profiling 
such as ATAC-seq to map accessible DNA (equivalent 
to DNase hypersensitive sites) [4], and iChIP-seq [7] or 
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recovery via protection (RP)-ChIP-seq and favored 
amplification RP-ChIP-seq (FARP-ChIP-seq) [8,96], it 
will now be possible to carry out epigenomic profiling 
using limited numbers of many different kinds of cells. 
In fact, as technologies progress to single-cell approaches, 
cell numbers will be further reduced. A single-cell 
method for ATAC-seq has just been described [96]. How-
ever, single cell methods always require a group of similar 
cells to obtain average signatures and this is expensive 
and computationally intense.
One important limitation of bead-based or 
FACS-based cell purification of distinct cell types is 
that antibodies to extracellular targets must be avail-
able to identify the desired cell types. Such antibodies 
are not in hand for many of the types of cells in the 
human body. This can be overcome by identifying cell-
type specific markers for each cell type. To this end, 
single cell RNA-seq data for cell populations from all 
over the body would be extremely valuable [3]. Principal 
component analysis of single cell populations will allow 
groups of cells with similar phenotypes to be identi-
fied. Such studies are being carried out for many tis-
sues, including the lung and brain [3,97], and will help 
clarify whether similar cell types from different organs 
or from different regions of the same organ are distinct, 
such as epithelial cells found in the bronchi versus the 
terminal bronchioles, or airway versus alveolar macro-
phages [98]. Single cell and low cell number techniques 
will also enable the epigenomic analysis of cells and tis-
sues from living humans through biopsies or different 
types of noninvasive sampling. This will allow a closer 
approximation of the natural state of tissues.
What about model organisms? Would it not be much 
easier to use genetically engineered animals with cell 
type-specifically labeled nuclei to investigate the com-
posite epigenomes of organs, and then to translate those 
findings to humans? Elegant procedures have been 
developed that allow nuclei to be labeled using animals 
engineered with cell type-specific promoters driving a 
nuclear envelope protein [99,100]. The tissues of interest 
can quickly be shredded to purify the labeled nuclei. 
Indeed, these model organism systems are very valuable, 
and can yield much information on the epigenetic encod-
ing of tissues, even from organisms distantly related to 
humans like flies and worms [17]. However, there are 
numerous differences even between human organs and 
their mammalian counterparts, and these differences 
will likely affect cellular epigenomes. In the lung, for 
example, the types of cells in different compartments 
can differ markedly between species [63–68].
Future perspective
The epigenomic profiling of cell types within organs, 
and ultimately of all the cell types in the human body, 
will provide key information supporting biomedical 
investigations. In the short term, the focus should be 
placed on elucidating the collective epigenomes for a 
limited number of adult individuals of both genders. 
However, such studies would form just the very begin-
ning of whole organism epigenomic analyses. We must 
build upon them by determining the comparative epig-
enomes from individuals of different ages, including 
embryos, infants, children and adolescents, different 
ethnicities and a wide range of environmental expo-
sures. Only then will we truly begin to grasp the range 
of epigenetic variation within and between individuals. 
Cost and complexity would prevent the examination 
of the large numbers of individuals usually enrolled 
in epidemiological studies. Instead, a limited num-
ber of epigenomes would be used to provide a basis 
for the investigation of very specific genomic regions 
or epigenetic marks in a large number of individuals. 
We anticipate that single-cell techniques will further 
evolve to allow the analysis of all epigenetic marks of 
interest in single cells, and that sequencing approaches 
will improve to enable the determination of numer-
ous epigenetic marks from each individual cell. This 
will, in turn, permit real-time sampling of dynamic 
epigenomes in patients to inform personalized medi-
cal strategies aimed at determination of disease risk, 
prevention and treatment.
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Executive summary
Examination of purified cell types is crucial for tissue regeneration research
•	 Epigenomic profiles are required to verify the integrity of stem cells and their derivatives used for cell-based 
therapies and tissue regeneration.
Identifying disease-associated epigenetic aberrations will require knowledge of progenitor cells 
& establishment of reference epigenomes
•	 Within a tissue distinct cell types can be affected by a variety of diseases.
•	 In order to establish how the epigenomes of diseased cells have been affected, the baseline epigenome of the 
cell of origin for each particular disease must be established.
Measuring the effects of environmental exposures requires knowledge of the baseline epigenomes of 
unexposed cell types
•	 Environmental exposures can be measured in disease-prone and surrogate tissues.
•	 Determination of epigenetic changes can inform prevention and therapeutic strategies.
Interpretations of the effects of genetic polymorphisms on disease risk requires knowledge of epigenetic 
marks in the risk-associated cell types
•	 Most SNPs lie in introns or intergenic regions.
•	 The biological function of SNPs, therefore, depends on whether they disrupt epigenetic regulatory elements 
in disease-associated cell types.
The complexities of determining comprehensive organ-specific epigenomes: the lung as an example
•	 Each organ consists of a wide variety of different cell types with distinct functions and disease predispositions.
•	 The epigenomes of closely related cells in the same organ compartment can differ dramatically.
•	 Different cell types must be individually purified and epigenomically characterized.
New approaches to obtaining cell-type-specific epigenomes
•	 FACS sorting and culture of purified cell types can provide cells for epigenomic analyses.
•	 Low-cell-number and single cell techniques are lowering the numbers of cells needed for epigenomic 
profiling, facilitating analyses.
Future perspective
•	 Efficient single-cell epigenome analysis will allow a personalized approach to assessment of genetic risk, 
environmental exposure and disease states.
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